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Dear Colleague,
It is a real honor and pleasure for me to
welcome you to Rare Cancers and Therapy. This
new journal represents an international effort to
focus on research and evidence-based medicine
in rare neoplasms. Rare Cancers and Therapy is an
international peer-reviewed, fully open access
journal with a rapid publication policy that
focuses on all topics related to low frequent
and/or orphan tumors. Original research,
outstanding reviews, case reports, and short
communications in the different areas of
knowledge of rare tumors are welcome,
including molecular biology, basic, preclinical
and translational research, epidemiology,
diagnosis, healthcare economics, and
treatment options based on a multidisciplinary
team approach and especially in new targeted
agents and personalized medicine.
The management of rare neoplasms is a real
challenge for physicians who need to deal with
them. In the literature there are no peer-
reviewed journals focused exclusively in the
publication of all kind of scientific
communications related to rare tumors.
Original research and, even more importantly,
referral reviews and specific case reports of rare
cancers management are distributed through all
available journals making it even more
complicated to make diagnosis and treatment
decisions in patients with rare neoplasms. One
of the main purposes of this new journal is to
join research and key opinion leaders’ reviews
in rare tumors giving health care professionals a
new and easy accessible tool to gain enough
knowledge to offer the best clinical practice in
the different settings of rare cancers.
In addition to classic manuscript
publication, Rare Cancers and Therapy will offer
a range of additional features designed to
increase visibility and readership. As such,
each paper is accompanied by a bulleted slide
summary giving a time-efficient overview of the
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content to a wider readership. All submissions
have the option to include slide sets, video
components, animations, and/or interactive
case studies.
I expect that the launching of Rare Cancers
and Therapy will fill the lack of an ‘‘exclusive
space’’ for all rare neoplasms in currently
available journals and will give the scientific
community the opportunity to join all available
data on these tumors in a unique tool,
facilitating physician’s daily clinical practice. I
really encourage all health care professionals
involved in the management of rare tumor
patients to join this initiative and reach the
objective to create a referral journal for rare
cancers and related therapies.
Jaume Capdevila
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